156 related articles for article (PubMed ID: 21955398)
1. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.
Wu Z; Doondeea JB; Gholami AM; Janning MC; Lemeer S; Kramer K; Eccles SA; Gollin SM; Grenman R; Walch A; Feller SM; Kuster B
Mol Cell Proteomics; 2011 Dec; 10(12):M111.011635. PubMed ID: 21955398
[TBL] [Abstract][Full Text] [Related]
2. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer.
Dasari SK; Joseph R; Umamaheswaran S; Mangala LS; Bayraktar E; Rodriguez-Aguayo C; Wu Y; Nguyen N; Powell RT; Sobieski M; Liu Y; Chowdhury MA; Amero P; Stephan C; Lopez-Berestein G; Westin SN; Sood AK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835335
[TBL] [Abstract][Full Text] [Related]
3. Identification of potent pan-ephrin receptor kinase inhibitors using DNA-encoded chemistry technology.
Madasu C; Liao Z; Parks SE; Sharma KL; Bohren KM; Ye Q; Li F; Palaniappan M; Tan Z; Yuan F; Creighton CJ; Tang S; Masand RP; Guan X; Young DW; Monsivais D; Matzuk MM
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2322934121. PubMed ID: 38701119
[TBL] [Abstract][Full Text] [Related]
4. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.
Faoro L; Singleton PA; Cervantes GM; Lennon FE; Choong NW; Kanteti R; Ferguson BD; Husain AN; Tretiakova MS; Ramnath N; Vokes EE; Salgia R
J Biol Chem; 2010 Jun; 285(24):18575-85. PubMed ID: 20360610
[TBL] [Abstract][Full Text] [Related]
5. Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate screen identifies EphA2 as a target for LAR in cell migration.
Lee H; Bennett AM
Mol Cell Biol; 2013 Apr; 33(7):1430-41. PubMed ID: 23358419
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of PLCγ1 by EphA2 Receptor Tyrosine Kinase Promotes Tumor Growth in Lung Cancer.
Song W; Kim LC; Han W; Hou Y; Edwards DN; Wang S; Blackwell TS; Cheng F; Brantley-Sieders DM; Chen J
Mol Cancer Res; 2020 Nov; 18(11):1735-1743. PubMed ID: 32753469
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic functions and therapeutic targeting of EphA2 in cancer.
Wilson K; Shiuan E; Brantley-Sieders DM
Oncogene; 2021 Apr; 40(14):2483-2495. PubMed ID: 33686241
[TBL] [Abstract][Full Text] [Related]
8. Receptor Tyrosine Kinase EPHA2 Drives Epidermal Differentiation through Regulation of EGFR Signaling.
Perez White BE; Cable CJ; Shi B; Ventrella R; Kaplan N; Kobeissi A; Higuchi Y; Balu A; Murphy ZR; Kumar P; Getsios S
J Invest Dermatol; 2024 Feb; ():. PubMed ID: 38520417
[TBL] [Abstract][Full Text] [Related]
9. Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer.
Veiga RN; de Azevedo ALK; de Oliveira JC; Gradia DF
J Mol Med (Berl); 2024 Apr; 102(4):479-493. PubMed ID: 38393661
[TBL] [Abstract][Full Text] [Related]
10. Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics.
Gridling M; Ficarro SB; Breitwieser FP; Song L; Parapatics K; Colinge J; Haura EB; Marto JA; Superti-Furga G; Bennett KL; Rix U
Mol Cancer Ther; 2014 Nov; 13(11):2751-62. PubMed ID: 25189542
[TBL] [Abstract][Full Text] [Related]
11. EphA2 as a phase separation protein associated with ferroptosis and immune cell infiltration in colorectal cancer.
Li Y; Peng Q; Wang L
Aging (Albany NY); 2023 Nov; 15(22):12952-12965. PubMed ID: 37980165
[TBL] [Abstract][Full Text] [Related]
12. Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas.
Srivastava S; Pang KM; Iida M; Nelson MS; Liu J; Nam A; Wang J; Mambetsariev I; Pillai R; Mohanty A; McDaniel N; Behal A; Kulkarni P; Wheeler DL; Salgia R
iScience; 2020 Nov; 23(11):101692. PubMed ID: 33196021
[TBL] [Abstract][Full Text] [Related]
13. Phosphotyrosine proteomics in cells synchronized at monopolar cytokinesis reveals EphA2 as functioning in cytokinesis.
Hasegawa N; Hongo M; Okada M; Kuga T; Abe Y; Adachi J; Tomonaga T; Yamaguchi N; Nakayama Y
Exp Cell Res; 2023 Nov; 432(1):113783. PubMed ID: 37726045
[TBL] [Abstract][Full Text] [Related]
14. Optimization of the Lead Compound NVP-BHG712 as a Colorectal Cancer Inhibitor.
Tröster A; DiPrima M; Jores N; Kudlinzki D; Sreeramulu S; Gande SL; Linhard V; Ludig D; Schug A; Saxena K; Reinecke M; Heinzlmeir S; Leisegang MS; Wollenhaupt J; Lennartz F; Weiss MS; Kuster B; Tosato G; Schwalbe H
Chemistry; 2023 Apr; 29(23):e202203967. PubMed ID: 36799129
[TBL] [Abstract][Full Text] [Related]
15. A novel pipeline for prioritizing cancer type-specific therapeutic vulnerabilities using DepMap identifies PAK2 as a target in head and neck squamous cell carcinomas.
Sannigrahi MK; Cao AC; Rajagopalan P; Sun L; Brody RM; Raghav L; Gimotty PA; Basu D
Mol Oncol; 2024 Feb; 18(2):336-349. PubMed ID: 37997254
[TBL] [Abstract][Full Text] [Related]
16. Proteome-based molecular subtyping and therapeutic target prediction in gastric cancer.
Hu C; Song J; Kwok T; Nguyen EV; Shen X; Daly RJ
Mol Oncol; 2024 Apr; ():. PubMed ID: 38627210
[TBL] [Abstract][Full Text] [Related]
17. Personalized Network Modeling of the Pan-Cancer Patient and Cell Line Interactome.
Bhattacharyya R; Ha MJ; Liu Q; Akbani R; Liang H; Baladandayuthapani V
JCO Clin Cancer Inform; 2020 May; 4():399-411. PubMed ID: 32374631
[TBL] [Abstract][Full Text] [Related]
18. Comprehending Meningioma Signaling Cascades Using Multipronged Proteomics Approaches & Targeted Validation of Potential Markers.
Mukherjee S; Biswas D; Gadre R; Jain P; Syed N; Stylianou J; Zeng Q; Mahadevan A; Epari S; Shetty P; Moiyadi A; Roy Ball G; Srivastava S
Front Oncol; 2020; 10():1600. PubMed ID: 32974197
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer proteogenomic investigations identify post-transcriptional kinase targets.
Elmas A; Tharakan S; Jaladanki S; Galsky MD; Liu T; Huang KL
Commun Biol; 2021 Sep; 4(1):1112. PubMed ID: 34552204
[TBL] [Abstract][Full Text] [Related]
20. Optimized chemical proteomics assay for kinase inhibitor profiling.
Médard G; Pachl F; Ruprecht B; Klaeger S; Heinzlmeir S; Helm D; Qiao H; Ku X; Wilhelm M; Kuehne T; Wu Z; Dittmann A; Hopf C; Kramer K; Kuster B
J Proteome Res; 2015 Mar; 14(3):1574-86. PubMed ID: 25660469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
